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Abstract: Epitope mapping allowed the location of antigenic determinants on a protein macromolecule to be identifi ed. In 
particular, pepscan techniques that utilize a series of overlapping peptides, help detect key amino acid residues that are 
important in antibody recognition and binding. In a previous study, we employed 15-mer peptides spanning the entire length 
of IgG1Fc to ascertain successfully the target epitopes of isotypic/allotypic monoclonal reagents.
As an extension to this work we have used these peptides to evaluate the location of epitope targets of fi ve IgM rheumatoid 
factor antibodies (RFAbs). Overall, 2 antibodies, RFAb TS2 and TS1, detected a similar epitope within the CH3 
domain (360-KNQVSLTCLVKGFYP-374), whilst 1 (RFAb SJ1) recognised an epitope in the CH2 domain (294-
EQYNSTYRVVSVLTV-308). In contrast, 2 RFAbs, PRSJ2 and PRTS1 detected four and fi ve epitopes respectively within 
the Fc region. RFAb PRSJ2 recognised epitopes detected by RFAB TS2 and TS1 but also further epitopes in the CH2 domain 
(256-TPEVTCVVVDVSHED-270) and CH3 domain (418-QQGNVFSCSVMHEAL-432). Similarly, RFAb PRTS1 detected 
all four epitopes plus a fi fth in the CH3 domain (382-ESNGQPENNYKTTPP-396). In essence there was a consensus of 
target epitopes identifi ed by these rheumatoid factor antibodies. Interestingly, two epitopes (256–270, CH2 domain and 
360–374, CH3 domain) were novel in that they had not been identifi ed in previous pepscan studies. The other epitopes 
recognised, either overlapped or were immediately adjacent to previous epitopes detected by poly/monoclonal rheumatoid 
factor antibodies.
Molecular modelling (PCImdad) of IgG1Fc showed that all fi ve epitopes were exposed and surface accessible for antibody 
interaction. In addition, a bioinformatics analysis of the Fc region using ExPASy was employed to identify key antigenic 
determinants. This ‘in silico’ approach may provide a means of determining key regions without the need to develop 
overlapping peptides spanning the entire length of a macromolecule.
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Introduction
Rheumatoid arthritis (RA) is an autoimmune disorder, with chronic infl ammation of the synovial mem-
brane culminating in the pathological destruction of cartilage and bone in affected joints. Overall the 
resultant pain, loss of function and disability causes signifi cant morbidity and mortality. The aetiology 
of RA remains unclear, although a genetic predisposition, together with other triggers including viral 
and bacterial agents are considered to be contributory factors.
Rheumatoid factors (RFs), are detected in a large proportion of RA patients and provide a key sero-
logical marker for diagnosis [1]. RF antibodies have been shown to target the Fc region of IgG [6], 
typically the CH2/CH3 inter-domain region by inhibition studies, enzyme degradation and site-directed 
mutagenesis. They are mainly low affi nity IgM isotype, but may also be high affi nity IgG and IgA 
isotypes. RFs are naturally-occurring autoantibodies that are also found in healthy individuals where 
they are considered to facilitate competitive tolerance [3], increase the cytotoxicity of antiviral antibodies 
[4] and aid immune complex formation and presentation/elimination by phagocytic cells [5].
Epitope mapping studies have contributed to the identifi cation of potential antigenic sites of 
rheumatoid factors in the pathological mechanisms of rheumatoid arthritis. Crude techniques such as 
cyanogens bromide cleavage and enzyme degradation, have permitted the localisation of antibody 
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reactivity to given immunoglobulin fragments. But 
the development of pepscan methodologies, which 
use a series of overlapping synthetic peptides, have 
provided a systematic approach for identifying key 
amino acids in antibody recognition and binding. 
Table 1 summarises a number of eloquent studies 
[7–11] that have used polyclonal/monoclonal 
rheumatoid factors which highlight CH2 and CH3 
target epitopes on IgG1 Fc. Moreover, Table 1 gives 
details of three antigenic regions on IgG1 Fc pre-
viously identifi ed through pepscan by monoclonal 
anti-IgG reagents MAbs: G7C, PNF69C and 
A57H) [7,9]. Interestingly, these epitopes when 
visualised through molecular modelling [1] were 
adjacent to, or overlapped with, amino acids 
identifi ed by polyclonal rheumatoid factors.
As an extension to our work, we have undertaken 
pepscan analysis of fi ve Fc-binding rheumatoid 
factor antibodies [12] and compared their reactivity 
against previously identifi ed RF epitopes. A molec-
ular modelling programme (IMDAD) [7] was used 
to locate the potential target epitopes of these anti-
bodies as antigenic ‘hot spots’ within the IgG1 Fc 
macromolecule. It is recognised that pepscan 
Table 1. Rheumatoid factor and anti-Fc target epitopes on IgG1.
Details/Amino acids Comments Reference
Regions on IgG1Fc identifi ed 
by RFs and mouse MAbs 
overlap or are adjacent
Review of RFs; composite molecular 
modelling of poly/monoclonal target RF 
epitopes plus anti-IgG MAbs.
Westwood et al. 2006
[1]
KPREE (290–294) Identifi ed by anti-CH2 MAbs G7C, JD312 in 
pepscan (biotinylated 15 mers)
Nelson et al. 2003 [7]
KAKGQPR (338–344) Detected by pan-IgG/anti-G3m(u) MAbs 
PNF69C, PNF110A.
H (435) + other residues
Ile (253)
28 monoclonal IgM RF from healthy donors 
immunized with mismatched RBCs ‘HID-RF’. 
Most recognise Ga epitope, reactivity profi le 
similar to RFs from WM but differ to RA-RFs.
Bonagura et al. 1998
[8]
SNGQPENN (383–390) Epitope identifi ed by pan-IgG MAb A57H 
against 15-mer biotinylated IgG1peptides.
Nelson et al. 1997 [9]
PREPQVY (343–349)
PQVYTLP (346–352)
TLPPRSE (350–356)
DGSFFLY (401–407)
WQQGNVF (417–423)
CSVMHEG (425–430)
EGLHNHY (430–436)
KSLSLSP (439–446)
Polyclonal IgM RF from 10 patients with RA 
showed reactivity to a number of overlapping 
7-mer peptides in the CH3 domain using a 
pin-based ELISA. 7 monoclonal RF exhibited 
more restricted specifi city e.g. D53 to 
DGSFFLYSKL (401–410), RFH4 to 
DKSRWQQ (413–419) to peptides largely 
detected by polyclonal RFs.
Peterson et al. 1995
[10]
NQVSLTC (361–367)[X]
VSLTCLV (363–369)[X]
GSFFLYS (402–408)[Y]
FFLYSKL (404–410)[Y]
NVFCSV (421–427)
SVFLFPP (239–245)
KFNWYVD (274–280)
NSTYRVVSV (297–305)
VLTVLHQNWL (305–314)
Reactivity profi le of anti-IgG1 MAb HP6069 
also tested in this system that recognised 5 key 
peptides (2 sets of peptides were continuous 
with overlapping residues, see [X] and [Y]).
Polyclonal IgM RF from 10 patients with RA. 
Identical study to above for for CH2 domain. 
A panel of monoclonal RFs exhibited 
restricted specifi city: WLDGKE (313–318) 
FLFPPKP (241–247) NWYVDGV (276–282) 
YRVVSVL (300–306) NWLDGKE (312–318) 
or scattered reactivity to peptides detected by 
polyclonal RFs
Willams and Malone, 
1994 [11]
LFPPKPK (242–248)
PQVKFNW (271–277)
NAKTKPR (286–292)
KAKGQPR (338–344)[Z]
MAb HP6069 recognised at least 4 epitopes 
plus EKTISKA (333–339). Note that 
peptide [Z] also identifi ed by MAb PNF69C.
Amino acids presented in single amino acid code plus Eu reference numbering.
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remains an expensive investigative tool. Conse-
quently, we evaluated a bioinformatic approach 
[13,14] to investigate potential antigenic targets. 
Overall, ‘in silico’ analysis favourably highlighted 
epitopes identifi ed by pepscan studies.
The rationale for these analyses has been to 
identify possible unique or overlapping regions of 
antigenicity on IgG Fc region with the view to 
facilitating possible peptides for therapeutic uses.
Materials and Methods
Rheumatoid factor antibodies
Rheumatoid factor IgM antibodies (RFAbs) were 
kindly provided by Professor JB Natvig 
(Rikshospitalet University Hospital, Institute of 
Immunology, University of Oslo, Norway). Details 
of the characterisation and purifi cation of these 
antibodies TS2, TS1, SJ1, PRSJ2 and PRTS1 has 
previously been reported [12]. In particular RFAbs 
TS2, TS1 and SJ1 were monospecifi c with regard 
to their reactivity against native IgG, whilst RFAbs 
PRSJ2 and PRTS1 were polyspecifi c.
Synthetic peptides
Ninety four overlapping 15-mer peptides corre-
sponding to the Fc region of IgG1 NIE were kindly 
provided by Mimotopes Pty Ltd. Peptides were 
initially reconstituted in DMSO and then diluted 
in citrate phosphate buffer as previously described 
[7]. Peptides spanned the CH2 and CH3 domains, 
beginning 238-PSVFLFPPKPKDTLM-252 and 
terminating 424-FSCSVMHEALHNHYT-438, 
with an offset of 2. All amino acids were related 
to the Eu protein numbering index [15].
Pepscan assay
An ELISA based assay for each overlapping 
peptide was used as previously described [7]. In 
brief, biotinylated peptides were coated onto strep-
tavidin coated plates, blocked with bovine serum 
albumin in 0.1 M PBS pH 7.2 and incubated with 
purifi ed antibodies PRSJ2, PRTS1, TS2, TS1 and 
SJ1 diluted to the following optimal working con-
centrations (7.3, 3.1, 46, 38 and 2.1 μg/ml) respec-
tively. Following washing and addition of 
anti-human HRP-conjugate and then substrate, 
plates were read at 405 nm (Titertek Multiscan). 
Optical density values were expressed as 0–2 OD 
Units. The OD values obtained from control RFAbs 
(SJ3, TS3, KL2 [12]) that exhibited minimal activ-
ity in pepscan, were used to determine a mean value 
for each peptide which was subtracted from all 
other pepscan profi les. Pepscan profi les for controls 
highlighted background activity: mean 0.05 OD 
Units. Control isotype matched RFAbs have 
similarly been shown to bind to native IgG [12].
PCImdad display
A PC interactive molecular display and design 
programme (PCImdad) was kindly provided by 
Dr. Michael Levitt and used as previously described 
[7]. The software utilised the Brookhaven Protein 
Data Bank (PDB fi les) for the coordinates of mac-
romolecules. In brief, the PDB fi le 1Fc1 (Deisen-
hofer IgG1 Fc sequence [16]) was selected and 
displayed in space-fi lling mode. Key amino acids 
derived from pepscan, bioinformatic analysis and 
published data were then highlighted using the 
command language provided by the manufacturer 
(M. Levitt, Molecular Applications Group, Stan-
ford University, U.S.A). Overall both Deisenhofer 
IgG1 Fc and protein Fc NIE were broadly similar 
in sequence but with variation in allotype; IgG1 
Deisenhofer Fc: non-G1m(a), NIE Fc: G1m(a).
Bioinformatic analysis
The protein sequence of IgG Fc (accession number 
AF150959-1) was extracted from the NCBI/
Genbank online database (www.ncbi.nlm.nih/). In 
silico analysis was performed using the bio-
computing software programmes available 
online at http://www.expasy.ch/cgi-bin/protscale.pl. 
The algorithms used included hydrophilicity, 
residue polarity, solvent accessibility and fl exibility 
index for primary structure. Threshold values 
were determined as the top 25%, 30% and 40% 
of peaks as suggested by Alix 1999 [17]. In 
addition, propensity for ß-turns was evaluated 
using BetatPred2 available at http://imtech.res.
in/raghava/betaturns. Using these parameters a 
region was considered antigenic when four or more 
of these properties were above threshold values or 
showed evidence of ß-turns.
Results
Pepscan profi ling
All fi ve rheumatoid factors (RFAbs) generated pep-
scan profi les when using IgG1 Fc overlapping pep-
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tides. RFAb TS2 (Fig. 1a) showed reactivity to an 
antigenic region within the CH3 domain encompassed 
by peptides 61 and 62 (358-LTKNQVSLTCLVKG-
FYP-374) (Table 2). A maximum signal intensity of 
0.2 OD units was observed to peptide 62. In the case 
of RFAb TS1, an identical reactivity profi le was 
shown (Fig. 1b) but with a weaker signal intensity 
of 0.12 OD units to peptide 62. Furthermore it was 
noted that RFAb TS1 showed reactivity (0.25 OD 
units) to peptide 85: residues 406-LYSKLTVDK-
SRWQQG-420. RFAb SJ1 (Fig. 1c) showed reactiv-
ity to a single region within the CH2 domain. Our 
data highlighted that RFAb SJ1 identifi ed a potential 
antigenic region bound by peptides 28–31 that 
included residues 292-REEQYNSTYRVVSVLTV-
LHQD-312. The highest signal intensity (0.14 OD 
units) was observed for peptide 29 (Table 2). Over-
all, antibodies TS2, TS1 and SJ1 appeared to be 
specifi c for a single epitope.
In contrast, RFAb PRSJ2 showed antibody 
reactivity to four potential antigenic regions 
(Fig. 1d) that encompassed residues 252-MISRT-
PEVTCVVVDVSHEDPEVK-274 (CH2 domain), 
290-KPREEQYNSTYRVVSVLTVLHQD-
WLNG-316 (CH2 domain), 360-KNQVSLT-
CLVKGFYPSD-376 (CH3 domain)  and 
418-QQGNVFSCSVMHEALHN-436 (CH3 
domain). For this antibody, maximum signal inten-
sities of 0.74, 0.15, 0.34 and 0.94 OD units were 
observed to peptides 10, 29, 63, and 91 respec-
tively. Likewise RFAb PRTS1 broadly exhibited a 
similar reactivity profi le to these four regions 
(Fig. 1e), but with generally lower OD values: 0.44, 
0.29, 0.42 (for peptide 62) and 0.14 OD units. 
However, RFAb PRTS1 also recognised a fi fth 
antigenic region. The latter was detected in peptide 
73: 382-ESNGQPENNYKTTPP-396, with a signal 
intensity of 0.12 OD units.
When taken together our data (Table 2) shows 
a broad consensus of 4 potential antigenic 
regions or epitopes that were identified by 
our RFAbs. Clearly a fi fth epitope was solely 
identifi ed by RFAb PRTS1. In summary, the fol-
lowing peptides were considered potential target 
epitopes and designated (i) 256-TPEVTCVVVD-
VSHED-270, (ii) 294-EQYNSTYRVVSVLTV-
308, (iii) 360-KNQVSLTCLVKGFYP-374 (vi) 
382-ESNGQPENNYKTTPP-396 and (v) 418-
QQGNVFSCSVMHEAL-432.
PCImdad display of key antigenic 
sites
The location and surface topography of RFAb tar-
get epitopes identifi ed through pepscan in this study 
were visualised on an IgG molecule using the space-
fi lling mode (Fig. 2a, b, c). The sequence (i) 256-
TPEVTCVVVDVSHED-270, was present on an 
exposed segment  of  the  fx2 β -pleated 
face and b2 bend (or loop) of the CH2 domain 
Figure 1. Pepscan profi le of RFAbs TS2 (a), TS1 (b), SJ1 (c), PRSJ2 
(d), PRTS1 (e). Vertical axis: optical density (0–2 OD) units (note 
scale on figures highlight 0–2000), horizontal axis: peptide 
number.
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whilst sequence (ii) 294-EQYNSTYRVVSVLTV-
308, was located on the b4 loop that bridged 
the fx3 and fx4 faces of the CH2 domain. 
Both sequences were solvent accessible. 
Sequences (iii) 360-KNQVSLTCLVKGFYP-374, 
(iv) 382-ESNGQPENNYKTTPP-396 and (v) 418-
QQGNVFSCSVMHEAL-432, were present on 
exposed segments on the CH3 domain. Sequence 
(iii) was located on part of the b1 loop and to a large 
extent on the fx2 face whereas sequence (iv) was 
located largely on the b3 loop and a small segment 
of the fx3 β-pleated face. Sequence (v) was located 
at the C-terminal of the IgG1 Fc macromolecule 
and included part of the fy2 face and b6 segment 
of the CH3 domain. All regions were thus capable 
of interaction with antibody/rheumatoid factors.
Bioinformatic (in silico) analysis
In silico analysis of IgG1 Fc highlighted a total of 
11 epitopes based on four out of fi ve parameters 
being satisfi ed. Overall the threshold applied for 
plots of hydrophilicity, accessibility, fl exibility and 
polarity determined the number of additional 
peptides that could be highlighted as potentially 
antigenic (Table 3). At 25% (high stringency) 
(Alix, 1999 [17]), 5 antigenic regions were 
identifi ed whereas at 30%, 3 further epitopes were 
identifi ed. An additional 3 epitopes were highlighted 
when a low threshold was applied (40%).
Discussion
Rheumatoid arthritis (RA) affects 0.5%–1% of the 
British population with about 75% of patients being 
rheumatoid factor (RF) positive [1,18]. Clearly 
RF is not exclusive to RA but found in other 
diseases such as Sjogren’s syndrome and mixed 
cryoglobulinemia, and shown to be transiently 
increased in a number of infectious diseases 
[19,20]. Here, it is possible that RF may have a 
benefi cial role in the resolution of disease. In the 
acute stage of RA, IgM RF is produced that is of 
low affi nity and as the disease progresses, class 
Table 2. Comparison of RFAb reactivity against IgG1 peptides.
Reactivity of RFAb
Peptide Amino acid TS2 TS1 SJ1 PRSJ2 PRTS1
8 252-MISRTPEVTCVVVDV-266 +
9 254-SRTPEVTCVVVDVSH-268 +
10 256-TPEVTCVVVDVSHED-270 + +
11 258-EVTCVVVDVSHEDPE-272 + +
12 260-TCVVVDVSHEDPEVK-274 + +
27 290-KPREEQYNSTYRVVS-304 +
28 292-REEQYNSTYRVVSVL-306 + +
29 294-EQYNSTYRVVSVLTV-308 + + +
30 296-YNSTYRVVSVLTVLH-310 + + +
31 298-STYRVVSVLTVLHQD-312 + + +
32 300-YRVVSVLTVLHQDWL-314 + +
33 302-VVSVLTVLHQDWLNG-316 + +
61 358-LTKNQVSLTCLVKGF-372 + + +
62 360-KNQVSLTCLVKGFYP-374 + + + +
63 362-QVSLTCLVKGFYPSD-376 + +
73 382-ESNGQPENNYKTTPP-396 +
89 414-KSRWQQGNVFSCSVM-428 +
90 416-RWQQGNVFSCSVMHE-430 +
91 418-QQGNVFSCSVMHEAL-432 + +
92 420-GNVFSCSVMHEALHN-436 +
Peptides are numbered according to the EU protein index. + highlights reactivity against peptides ascertained through pepscan, + indicates 
highest OD value exhibited by a given rheumatoid factor antibody (RFAb). Overall fi ve peptide regions are observed (highlighted in grey).
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switching occurs (to IgG or IgA) together with 
somatic mutation of complimentary determining 
residues yielding high affinity RF antibodies. 
Overall, these facts suggest an antigen-driven 
immune response. The binding of RFs to IgG has 
been located to the CH2/CH3 interdomain region 
that is also associated with the docking of proteins 
such as Staphylococcus protein A. In the case of 
RF-AN (derived from an EBV transformed B cell 
from an RA patient), the reactivity is isolated to 
IgG1, 2 and 4 suggesting the importance of histi-
dine 435 in the Ga target epitope [21].
Epitope mapping studies have provided a sub-
stantial list of Fc-related peptides that could be 
important for RF binding [7–11]. In the present 
study, we have used 15-mer overlapping peptides 
of IgG1 Fc to explore the reactivity of fi ve IgM 
RFs and identify a consensus of potential RF amino 
acid regions/epitopes. Three antibodies exhibited 
specifi city to a single domain: both RFAbs TS2 
and TS1 to a region in the CH3 domain, epitope 
(iii) 360-KNQVSLTCLVKGFYP-374 and RFAb 
SJ1 to a region in the CH2 domain, epitope (ii) 
294-EQYNSTYRVVSVLTV-308. Overall, this 
data was consistent with the monospecifi city of the 
rheumatoid factors [12]. Interestingly epitope (iii) 
was adjacent to amino acids previously cited RF 
antigenic sites but novel in terms of its position 
(Fig. 3) and was present in IgG1, 2, 3 and 4 sub-
classes. In contrast epitope (ii) highlighted amino 
acid variations between IgG subclasses and was 
located in a region previously identifi ed by poly-
clonal and monoclonal rheumatoid factors. RFAb 
PRSJ2 showed strong reactivity for epitopes (ii) 
and (iii), but also highlighted reactivity for epitopes 
(i) 256-TPEVTCVVVDVSHED-270 and (v) 418-
QQGNVFSCSVMHEAL-432. Again epitope (i) 
was novel in terms of its CH2 position in com-
parison to previously cited RF epitopes and was 
distal to lower hinge region residues associated 
with Fc-receptor (FcγRI) binding (234-LLGG-237) 
[22,23] (Fig 3). Epitope (v) was located at the 
C-terminal region of the CH3 domain and in a zone 
previously shown as a potential site for RF activity. 
RFAb PRTS1 showed lower reactivity in terms of 
OD units as compared to RFAb PRSJ2 and exhib-
ited cross-reactivity to epitopes (i), (ii), (iii), 
(v) plus epitope (iv) 382-ESNGQPENNYKTTPP-
396. Again the pepscan profiles of both IgM 
antibodies were consistent with the polyspecifi c 
nature identifi ed by Soltys et al. 1994 [12]. It is 
plausible that these antibodies are of low affi nity 
Figure 2. Molecular modelling of monoclonal rheumatoid factor 
epitopes i, ii, iii, iv, v. For optimal viewing, epitopes are presented as 
shown i and iii (Fig. 2a), ii and iv (Fig. 2b) and v (Fig. 2c). The IgG 
Fc ‘horse-shoe’ like structure has also been rotated 45°.
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and may explain the cross-reactivity exhibited in 
our study. Epitope (iv) has not previously been 
identifi ed by rheumatoid factor antibodies but by 
a monoclonal antibody, A57H, generated from a 
mouse immunized with a purified IgG1 Fc 
myeloma protein [9]. Clearly a caveat of pepscan 
is that it provides a picture of antibody reactivity 
to linear stretches of amino acids. Evidently a given 
antibody may recognise adjacent peptides (pos-
sessing a particular amino acid motif), however 
there also examples of antibodies (e.g. monoclonal 
antibody HP6069 [11]) that recognise more that 
one region. This could be due to a number of fac-
tors including low affi nity interactions, recognition 
of similar structures (despite different amino acids) 
[24] and the recognition of epitopes not usually 
exposed or hidden in the native protein. It is also 
possible that the assay system and orientation of 
peptides could contribute to unexpected reactivity 
or indeed poor reactivity for some peptides.
Molecular modelling shows that all fi ve RFAb 
epitopes were located on exposed surfaces on IgG 
Fc and accessible for antibody interaction (Fig. 2). 
The opportunity to highlight key residues provides 
a useful adjunct to epitope mapping in providing 
their location in a three-dimensional setting. Inter-
estingly epitope (ii) possessed the amino acid 
asparagine 297 that is associated with glycosyl-
ation of IgG [25] (Fig. 3). The fact that this anti-
body bound to IgG1 in vitro suggests that the epitope 
was not masked or sterically hindered by the attach-
ment of carbohydrate moieties. Epitope (iii) was 
proximal to the G1m(a) allotypic region and epit-
ope (v) included the non-G1m(x) residue, alanine 
431, and was on the same β-strand as histidine 435 
(Fig. 3). Both the G1m(a) motif, 356-DELTK-360, 
alanine/glycine 431 and histidine 435 residues are 
solvent accessible [7,26]. Overall, for all fi ve RFAb 
epitopes there were few amino acid variations 
between isotypes suggesting that these antibodies 
would bind to all four subclasses.
Bioinformatic analysis uses computational 
algorithms to predict regions of hydrophilicity, 
accessibility, polarity, fl exibility and β-turns that 
in turn may identify potential antigenic regions of 
proteins. This in silico approach has been 
successfully used to determine likely antigenic ‘hot 
spots’ on auto-antigens such as cardiac myosin 
[27], and antigenic sites on viruses [13]. In adopt-
ing this approach, we noted a degree of plasticity 
in peptide regions selected using ExPASy 
depending on the stringency (or threshold) set. 
At a threshold of 25%, as initially highlighted 
by Alix (1999), 5 peptides were identified of 
which 3: 286-NAKTKPREEQYNSTY-300, 349-
YTLPPSRDELTKNQVS-364 and 263-VVD-
VSHEDPEVKFNW-277 either overlapped or were 
a few residues upstream or downstream to RFAb 
epitopes (ii), (iii) and (i) respectively. At a thresh-
old of 30%, 3 additional epitopes were identifi ed 
that overlapped with RFAb epitopes (ii) and (v). 
Again a number of epitopes selected through 
bioinformatics were identifi ed as key epitopes 
by mouse MAbs G7C, PNF69C and A57H. 
When a low threshold was applied (40%), further 
epitopes (391-YKTTPPVLDSDGPFF-405 and 
Table 3. Bioinformatic analysis of IgG1Fc.
Threshold Position Amino acid sequence of antigenic site
25% 286–300 (CH2) NAKTKPREEQYNSTY
333–347 (CH2/CH3) EKTISKAKGQPREPQ
349–364 (CH3) YTLPPSRDELTKNQVS
380–394 (CH3) EWESNGQPENNYKTT
263–277 (CH2) VVDVSHEDPEVKFNW
30% all sequences at 25% plus:
311–325 (CH2) QDWLNGKEYKCKVSN
407–421 (CH3) YSKLTVDKSRWQQGN
240–254 (CH2) VFLFPPKPKDTLMIS
40% all sequences at 25% and 30% plus:
324–338 (CH2) SNKALPAPIEKTISK
391–405 (CH3) YKTTPPVLDSDGPFF
433–447 (CH3) HNHYTQKSLSLSPGK
Peptides are numbered according to the EU protein index.
40
Nelson et al
Clinical Medicine:  Arthritis and Musculoskeletal Disorders 2008:1 
433-HNHYTQKSLSLSPGK-447) were identifi ed 
that overlapped to some extent with poly/mono-
clonal RFs from previous studies. In a recent study 
on the human immunodefi ciency virus (HIV-1), 
bioinformatics analysis was used to identify key 
peptides that were synthesised and assessed against 
HIV-1 positive serum. In this particular study, the 
sera of HIV-1 patients bound to a large proportion 
of peptides, although a few peptides were negative. 
Unfortunately no mention of the stringency applied 
in the selection of peptides was reported. In our 
proof of principle study, a threshold of 30% 
appeared to be an optimal ‘benchmark’ for high-
lighting crucial epitopes on IgG1 Fc. With less 
stringency, other peptides may be highlighted that 
could be of less importance in vivo e.g. epitope 
324-SNKALPAPIEKTISK-338 exhibited no over-
lap with RF epitopes. Overall, bioinformatics may 
provide a guide of antigenic regions that are likely 
to be found in vivo with the caveat of a suitable 
threshold to exclude unnecessary peptides. This 
approach could provide a way forward in selecting 
key epitopes on large macromolecules e.g. 
autoantigenic epitopes in RA and systemic lupus 
erythematosus, without the need (and expense) for 
numerous overlapping peptides spanning the entire 
length of a protein [28,29].
In essence, epitope mapping and molecular 
modelling provide a useful means of identifying 
key epitopes for antibody-antigen interaction and 
binding. Our study differed from some previous 
pepscan studies in employing 15-mer (as com-
pared to 7-mer) overlapping peptides. It is plau-
sible that longer peptides may provide better 
opportunities for displaying epitopes since some 
conformation, in the context of the native protein, 
could be adopted. In addition we used the strategy 
of biotinylated peptides. Again this ensured 
maximum display of peptide as opposed to using 
hydrophobic interactions of peptide and plastic 
plate that could mask the salient amino acid resi-
dues. Clearly further work using shorter peptides 
and inhibition studies could help further refi ne the 
RFAb epitopes identifi ed. It is possible that the 
231 Eu number    241              251                        261                         271
Cγ1a  APELLGGPSV FLFPPKPKDT LMISRTPEVT  CVVVDVSHED PQVKFNWYVD
+++++++++                                                                                                ++++++++
Cγ1b                PSV  FLFPPKPKDT  LMISRTPEVT  CVVVDVSHED PEVKFNWYVD 
***********                                                                                                ************ 
281         291    301                         311                            321
Cγ1   GVQVHNAKTK PREQQYNSTY  RVVSVLTVLH  QNWLDGKEYK CKVSNKALPA
+++                                                          +++++++++++                   +/+++++++++/+
Cγ1   GVEVHNAKTK  PREEQYNSTY  RVVSVLTVLH  QDWLNGKEYK  CKVSNKALPA
**************/*/****************
331            341               351                          361                          371
Cγ1   PIEKTISKAK GQPREPQ VYT LPPSRQQMTK NQVSLTCLVK  GFYPSDIAVE
Cγ1   PIEKTISKAK   GQPREPQVYT  LPPSRDE LTK   NQVSLTCLVK   GFYPSDIAVE 
****/******/*****/*******
381    391                        401                       411                            421
Cγ1   WESNDGEPEN YKTTPPVLDS  DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE
+++++++++++++         +++++++++++
Cγ1   WESNGQ  PEN NYKTTPPVLDS  DGSFFLYSKL TVDKSRWQQG   NVFSCSVMHE
**********                                **************   ********** 
431                          441
Cγ1    ALHNHYTQKS  LSLSPG       protein  Eu   
Cγ1    ALHNHYTQKS  LSLSPGK    protein  NIE 
**********       ***********                  
Figure 3. Epitopes identifi ed through bioinformatics and Pepscan. Key: bioinformatic epitopes at 25% threshold XX (boxed, shaded) and at 
30% YY (boxed, non-shaded). XX = reactivity of RFAbs in this paper highlighted on protein NIE only. X (italic) = nuance between Eu and 
NIE. ** reactivity of polyclonal and ++ monoclonal RFs from previous studies [7–10]. IgG proteins: Cγ1a reference protein Eu IgG1 Fc accession 
number AF150959–1, Cγ1b protein NIE (used for pepscan).
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peptides identifi ed may have some potential as 
therapeutic agents [30] should they prove to 
modulate RF production [31]. It would be interest-
ing to evaluate IgG RFAb’s to evaluate an 
increased reactivity/affi nity to similar or other 
epitopes. Evidently the spectrum of epitopes might 
alter on IgG, and other macromolecules in the 
pathogenesis of RA, due to epitope spreading 
[32,33]. What causes the initial antigenic insult in 
RA remains unknown, although there is a possible 
mechanism of molecular mimicry [34]. Prelimi-
nary alignment analysis (using ExPASy) shows 
that some RFAb epitopes (i), (ii) and (iv) share 
some homology with human endogenous retrovi-
ruses (HERVs): TPEAT epitope (i), NGQP epitope 
(iv) with HERV-K10 and NQNSLTC epitope (iii) 
with HERV-L. Interestingly HERV-K10 has been 
implicated in RA and SLE [35,36,37]. This area 
warrants further investigation plus an assessment 
of cross-reactive epitopes with microbes and 
autoantigens. In addition, the application of bio-
informatics to identify key antigenic regions on 
host proteins and possible microbes may prove 
useful in other diseases such as multiple sclerosis 
and systemic lupus erythematosus.
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